ST. PETERSBURG, Fla.

佛罗里达州圣彼得堡

,

，

June 4, 2026

/PRNewswire/ --

/美通社/ --

ARTAN Bio

ARTAN生物

, a longevity biotechnology company based in St. Petersburg, Florida, today announced the completion of a $200,000 seed raise. The raise will fund preclinical advancement of ARTAN Bio's proprietary engineered suppressor platform, which targets nonsense mutations — a class of genetic errors responsible for premature protein translation stops that underlie a wide range of aging-related and genetic diseases..

总部位于佛罗里达州圣彼得堡的长寿生物技术公司ARTAN Bio今日宣布完成20万美元的种子轮融资。该笔资金将用于推进ARTAN Bio专有工程化抑制子平台的临床前研究，该平台靶向无义突变——这类基因错误会导致蛋白质翻译提前终止，是多种衰老相关疾病和遗传性疾病的根本原因。

About the Technology

关于该技术

ARTAN Bio has developed a novel engineered suppressor tRNA system (ARTAN-102) designed to selectively recognize disease-causing nonsense codons and restore normal protein translation. Unlike broad-spectrum approaches, ARTAN Bio's mutation-specific platform offers a targeted strategy with potential application across multiple aging-associated conditions.

ARTAN Bio 开发了一种新型工程化抑制性 tRNA 系统（ARTAN-102），旨在选择性识别致病性无义密码子并恢复正常的蛋白质翻译。与广谱方法不同，ARTAN Bio 的突变特异性平台提供了一种靶向策略，在多种衰老相关疾病中具有潜在应用前景。

The company has successfully completed initial in-cell validation of ARTAN-102 via an earlier seed raise with .

该公司已通过早期种子轮融资，成功完成了ARTAN-102的初步细胞内验证。

VitaDAO

VitaDAO

.

。

Proceeds from the raise will fund the next stage of development, including validation of the suppressor system in animal models, advancement toward a preclinical development candidate, and intellectual property filings to protect the platform's innovations.

此次融资所得将用于资助下一阶段的开发工作，包括在动物模型中验证抑制剂系统、推进临床前候选药物的研发，以及提交知识产权保护申请以保护该平台的技术创新。

Leadership Comments

领导层意见

'This raise marks an important inflection point for ARTAN Bio,' said

“此次融资标志着ARTAN Bio的一个重要转折点，”

Anthony Schwartz, Ph.D., Chief Executive Officer of ARTAN Bio.

安东尼·施瓦茨博士，ARTAN Bio 首席执行官。

'We are building a platform with real potential to address the genetic underpinnings of aging, and we're doing it through an open, community-driven model that hasn't been possible before. I look forward to sharing our progress with the global longevity and DeSci community at the

“我们正在构建一个具有真正潜力的平台，以应对衰老的遗传学基础，并通过一种前所未有的开放、社区驱动的模式来实现这一目标。我期待在……向全球长寿科学和去中心化科学（DeSci）社区分享我们的进展。”

NFC Summit

NFC峰会

(Non-

（非

Fungible

可互换的

Conference) in Lisbon on June 4th.'

会议）于6月4日在里斯本举行。

'Nonsense mutations represent a largely untapped vulnerability in aging and age-related disease,' said

“无义突变代表了衰老及年龄相关疾病中一个 largely 未被开发的脆弱性，” said

Michael Torres, Ph.D., Chief Scientific Officer of ARTAN Bio.

迈克尔·托雷斯博士，ARTAN Bio 首席科学官。

'Having validated our engineered suppressor system in cell models, we are now positioned to demonstrate its efficacy in vivo. This raise through VitaDAO's

在细胞模型中验证了我们设计的抑制系统后，我们现在准备展示其在体内的功效。此次融资通过 VitaDAO 进行

decentralized

去中心化

science model gives us the capital and the community to take that next step.'

科学模型为我们提供了资金和社区支持，以迈出下一步。

Anthony Schwartz, Ph.D. will present ARTAN Bio at the NFC Summit in Lisbon, Portugal on June 4th, 2026, where he will discuss the company's platform, its VitaDAO partnership, and the

安东尼·施瓦茨博士将于2026年6月4日在葡萄牙里斯本举行的NFC峰会上展示ARTAN Bio，届时他将讨论该公司的平台、其与VitaDAO的合作伙伴关系，以及

decentralized

去中心化

science model driving its development.

科学模型驱动其发展。

About the VITARNA

关于 VITARNA

Token

令牌

$VITARNA tokens represent fractions of governance rights over the Mutation-Specific Codon Suppression for Aging and Longevity IP-NFT. The primary issuance is offered via the

$VITARNA 代币代表对“针对衰老与长寿的突变特异性密码子抑制”IP-NFT 治理权的份额。首次发行通过以下方式提供：

Molecule AG platform

Molecule AG 平台

.

。

Token

令牌

holders participate in governance decisions including research prioritization, IP licensing strategy, and allocation of research funds — a model that democratizes early-stage biotech funding and aligns scientific progress with community stakeholders.

持有者参与治理决策，包括研究优先级设定、知识产权许可策略以及研究资金的分配——这一模式使早期生物技术融资民主化，并使科学进步与社区利益相关方保持一致。

About ARTAN Bio

关于 ARTAN Bio

ARTAN Bio is a longevity biotechnology company headquartered in St. Petersburg, Florida at

ARTAN Bio 是一家长寿生物技术公司，总部位于佛罗里达州圣彼得堡

spARK Labs

spARK实验室

by

由

ARK Invest

ARK Invest

. The company is developing mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions caused by nonsense mutations. ARTAN Bio's platform delivers engineered suppressor systems through clinically validated modalities to restore protein function in affected cells..

该公司正在开发突变特异性密码子抑制技术，以应对由无义突变引起的遗传性疾病和衰老相关病症。ARTAN Bio的平台通过临床验证的递送方式提供工程化抑制系统，从而在受影响细胞中恢复蛋白质功能。

About VitaDAO

关于 VitaDAO

VitaDAO is a

VitaDAO 是一个

decentralized

去中心化

autonomous organization dedicated to funding and advancing longevity science research. VitaDAO supports early-stage research projects through its IP-NFT model, enabling broad community participation in the governance of longevity IP. More information is available at vitadao.com.

一个致力于资助和推进长寿科学研究的自治组织。VitaDAO 通过其 IP-NFT 模式支持早期研究项目，使更广泛的社区能够参与长寿知识产权的治理。更多信息请访问 vitadao.com。

This press release is for informational purposes only. VITARNA tokens are not securities and this release does not constitute an offer or solicitation to purchase financial instruments.

本新闻稿仅供信息参考。VITARNA 代币并非证券，本新闻稿不构成购买金融工具的要约或招揽。

SOURCE ARTAN BIO

来源 ARTAN 简介

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示